GET DAILY SIGNALSTLRY vs YCBD: Weighing Scale and Stability Against Growth Potential
Key Takeaways
- Tickeron AI Verdict: TLRY stands out over YCBD due to its larger scale, diversified revenue streams, stronger liquidity position, and steadier market presence.
- TLRY runs a multi-segment platform across cannabis, beverages, and wellness, delivering fiscal-year revenue near $915 million, while YCBD remains a micro-cap CBD player with roughly $5.6 million in recent quarterly net sales.
- Both names are still unprofitable, yet TLRY maintains a much larger cash buffer and broader revenue base, whereas YCBD operates with a thinner balance sheet.
- YCBD shows faster percentage revenue growth and stands to benefit from a new federal Medicare CBD pathway, though its limited size and regulatory sensitivities add to the risk.
- Additional details on each name are available through TLRY Major News and TLRY Today's Price Move, as well as YCBD Major News and YCBD Today's Price Move.
- Traders interested in systematic approaches can review the Trending AI Robots page for context on how quantitative strategies are handling similar names.
Why Compare These Two Names?
Investors following the cannabis and hemp-derived wellness space frequently evaluate established, diversified operators against smaller, higher-growth pure plays. This comparison looks at TLRY (Tilray Brands, Inc.) and YCBD (cbdMD, Inc.), two listed companies that share some regulatory and consumer themes yet operate very different business models. Their relative performance and positioning can help clarify whether scale and diversification or growth potential and specialization better match specific objectives right now.
TLRY Overview and Recent Performance
TLRY, Tilray Brands, Inc., has shifted from a pure cannabis producer into a broader consumer packaged goods business that spans cannabis, craft beverages, and wellness items. The company reported record fiscal-year revenue near $915 million, driven by gains in distribution, beverages, and international medical cannabis. Management has highlighted ongoing international expansion, including stronger Canadian cultivation and wider European medical distribution, along with the integration of craft-beer acquisitions such as BrewDog. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Even with operational progress, the stock has faced ongoing pressure, declining roughly 50% through much of 2026 and sitting near its 52-week lows. Sentiment reflects continued unprofitability, intense competition in cannabis, and broader caution toward speculative names. Analysts remain split, with some holding buy ratings and others expressing caution, underscoring a company whose fundamentals are advancing but whose path to consistent profits is still unproven.
YCBD Overview and Recent Performance
YCBD, cbdMD, Inc., focuses on CBD and hemp-derived wellness products under brands that include cbdMD, Paw CBD, Bluebird Botanicals, and the Oasis THC beverage line. The company has posted double-digit year-over-year revenue growth, with recent quarterly net sales around $5.6 million and sequential improvement helped by the early-2026 integration of Bluebird Botanicals.
Recent trading has been shaped by regulatory steps, notably the launch of a federal Medicare pathway for hemp-derived CBD products that management sees as a longer-term opportunity. At the same time, the company continues to post operating losses and holds limited cash, while shifting state rules have increased compliance and repackaging costs. This mix of solid percentage growth, emerging catalysts, and a constrained balance sheet shapes YCBD’s risk-reward profile.
Head-to-Head Comparison
The clearest difference between the two is scale. TLRY generates hundreds of millions in quarterly revenue across multiple segments and regions, while YCBD operates at a much smaller level in a narrower CBD niche. That gap produces different risk profiles: TLRY gains from diversification and a larger cash cushion, whereas YCBD delivers faster relative growth but with thinner liquidity and greater exposure to any single regulatory or integration issue.
Growth drivers also vary. TLRY leans on international medical cannabis expansion and craft-beverage integration, while YCBD centers on hemp-derived wellness products and the emerging Medicare pathway. Both face regulatory and competitive pressures, yet YCBD’s micro-cap structure and concentrated exposure create comparatively higher downside risk.
Tickeron AI Verdict
Based on factors such as trend consistency, financial stability, catalyst breadth, and relative positioning, Tickeron’s AI framework would likely favor TLRY over YCBD in the current setting. Although both remain unprofitable and navigate regulatory uncertainty, TLRY’s diversified revenue, larger cash reserves, and expanding international reach offer a more stable base. YCBD’s quicker revenue growth and federal pathway catalyst are noteworthy, but its limited scale and balance sheet introduce more variability. On a relative, risk-adjusted basis, TLRY currently appears better positioned.
Exploring AI-Driven Trading Approaches
In my own work, I often review Tickeron’s Trending AI Robots to see how systematic strategies are positioned across volatile sectors like this one. The page highlights bots that have performed well in current conditions, each with its own style, timeframe, and watchlist. It provides a useful quantitative lens alongside traditional analysis when evaluating names such as these.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TLRY's Stochastic Oscillator penetrating overbought zone
The Stochastic Oscillator for TLRY moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Indicator exited the oversold zone, 39 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TLRY as a result. In 63 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TLRY just turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (7.271). P/E Ratio (-2.679) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis
Industry PharmaceuticalsGeneric
Advertisement